Invention Grant
- Patent Title: Suppression of prostate cancer using a targeted clostridial neurotoxin
-
Application No.: US14250954Application Date: 2014-04-11
-
Publication No.: US10550377B2Publication Date: 2020-02-04
- Inventor: Frederic Madec , Philip Lecane , Philip Marks , Keith Foster
- Applicant: IPSEN BIOINNOVATION LIMITED
- Applicant Address: GB Abingdon, Oxfordshire
- Assignee: IPSEN BIOINNOVATION LIMITED
- Current Assignee: IPSEN BIOINNOVATION LIMITED
- Current Assignee Address: GB Abingdon, Oxfordshire
- Agency: Barnes & Thornburg LLP
- Agent Gene J. Yao
- Priority: GB0810782.3 20080612; GB0820965.2 20081117
- Main IPC: C07K14/33
- IPC: C07K14/33 ; C12N9/50 ; C12N9/64 ; C07K7/08 ; C07K14/48 ; C07K14/575 ; C07K14/60 ; C07K14/65 ; C07K14/82 ; A61K38/00
Abstract:
The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
Public/Granted literature
- US20140219983A1 SUPPRESSION OF CANCERS Public/Granted day:2014-08-07
Information query
